Structured Biotech Investment
A $1M seed investment in a biotech targeting a $5B+ market with no approved therapy — backed by Mission BioCapital.
$1M
SPV Target
Seed round
$25K
Min. Commitment
Accredited investors only
~36 Mo
Liquidity Horizon
Series B optionality
$5B+
Market Opportunity
Cardiorenal TAM
Regeneron and Novartis are both running programs targeting the same receptor Laurel is pursuing. Laurel's approach is structurally differentiated — smaller format, better tissue access — the gap big pharma has been unable to close with conventional antibodies.
Novo Nordisk paid up to $2.1B for Corvidia and $1B for Cardior. BMS paid $13.1B for MyoKardia. Strategic buyers are actively hunting differentiated cardiovascular platforms.
In vivo PoC, Lead Selection, IND by end 2028. Each checkpoint is a go/no-go gate. Investors know exactly what success looks like at every stage.
SPV LPs receive pro-rata rights at Series B — enabling each investor to follow on, sell, or hold. You decide based on data, not a blind lock-up.
Insider access, not a blind pool.
Matthew Therkelsen is both co-founder of Laurel and principal of Taurus Bioventures. SPV investors gain access to a deal sourced from the inside — not a pitch deck cold-received from a broker.
Laurel is backed by Mission BioCapital — a specialist life science VC. SPV LPs invest alongside institutional capital already committed to this company. Institutional validation at the same entry price.
This is not a blind pool or a diversified fund. Investors know exactly what company, what stage, and what milestones their capital is funding. Every checkpoint is a go/no-go gate.
Developing a treatment for heart failure patients with kidney disease — a condition affecting 500,000+ people annually with no approved therapy that addresses both organs simultaneously.
Laurel's drug candidate is structurally differentiated — a smaller-format antibody engineered for superior kidney uptake, targeting the same receptor validated by active programs at Regeneron and Novartis.
Backed by Mission BioCapital, a specialist life science VC. Institutional validation at the same entry price.
Lead Indication
Acute Decompensated Heart Failure + Renal Impairment
$5B+ TAM
500K+ patients/year, ~$10K/year estimated price
Differentiated format
Smaller-format antibody engineered for kidney tissue penetration
Backed by Mission BioCapital
Specialist life science VC leading the seed round
Big pharma is paying 8-10 figure sums for cardiorenal assets with early clinical data. Laurel is building exactly this type of asset — at seed-stage entry price.
$13.1B
MyoKardia
Bristol Myers Squibb
Phase III cardiovascular data
Up to $2.1B
Corvidia
Novo Nordisk
Renal biomarker + inflammation data
Up to $1B
Cardior Pharma
Novo Nordisk
Phase 1b cardiac biomarker data
$260M
Cardurion Pharma
Series B Investors
Phase 2a cardiac biomarker data
Now
SPV Close
$1M Seed Investment
Q3 2026
Animal Study Data
Target engagement data in animal models
Q2 2027
Lead Selection
VHH optimization + IP filing
Q4 2028
Regulatory Filing Ready
IND submission package
2030
Series B
Liquidity optionality for LPs
Follow On
Exercise pro-rata rights and invest in Series B at validated asset value
Take Chips Off
Sell a portion of your pro-rata to Series B investors as a partial exit
Full Exit
Sell full pro-rata position to incoming Series B investors
Let It Ride
Hold your seed position and participate in Series A and beyond
01
Identify and characterize candidate drug molecules. 60+ AI-generated drug candidates already synthesized and ready for testing before SPV close — reducing early-stage risk.
02
Confirm the drug candidate works in cell and animal models. Data package generated by Q3 2026 — the first major milestone for LP review.
03
Optimize the lead candidate and file foundational patents before Series A.
This SPV is available to accredited investors with a $25,000 minimum commitment. Complete the form below to request the full investor package and subscription documents.
Request Investor Package